Fort, L.P. Neurocrine Biosciences Inc Transaction History

Fort, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $248,348 - $331,193	-3,118 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $249,577 - $286,790	-2,896 Reduced 48.15%	3,118 $299,000
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $310,590 - $355,183	-3,473 Reduced 36.61%	6,014 $585,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $40,807 - $55,640	-466 Reduced 4.68%	9,487 $923,000
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $310,703 - $387,279	3,575 Added 56.05%	9,953 $954,000
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $613,308 - $861,986	6,378 New	6,378 $613,000
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $18,975 - $29,070	-223 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $16,749 - $25,368	223 New	223 $19,000

632

93.9M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Fort, L.P., based on Form 13F filings with the SEC.

Stay updated on Fort, L.P. with notifications on news.